Compare Hard to Treat Diseases (HTDS) vs. Competitors

14 Followers

Comparison Results

HTDS

Hard to Treat Diseases

<$0.01

$5.48K

―

Scinai Immunotherapeutics

$2.87

$718.23K

―

-91.00%

―

PainReform

$0.99

$2.69M

-0.08

-87.34%

―

MSP Recovery

$0.01

$1.43K

―

-99.64%

―

NewcelX

$3.35

$15.40M

8.97

-84.58%

1 Buy

0 Hold

0 Sell

Moderate Buy

Virax Biolabs Group Ltd. Class A

$2.91

$3.23M

-0.08

-87.09%

―

xxxxxxxxxxxxx

HTDS vs VRAX

xxxxxxxxxxxxx

Performance Comparison

HTDS

Hard to Treat Diseases

―

SCNI

Scinai Immunotherapeutics

1.22

-13.38

-91.64%

PRFX

PainReform

0.88

-5.92

-87.06%

MSPR

MSP Recovery

0.01

-1.19

-99.17%

NCEL

NewcelX

2.96

-15.34

-83.83%

VRAX

Virax Biolabs Group Ltd. Class A

2.03

-14.00

-87.33%

Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts

Compare More Stocks >